We are live on ! Find out more
IHAM

Integral Health Asset Management Portfolio holdings

AUM $2.09B
1-Year Est. Return 112.84%
This Fund
S&P 500
This Quarter Est. Return
+14.55%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$1.05B
AUM Growth
-$24.6M
Cap. Flow
-$44M
Cap. Flow %
-4.18%
Top 10 Hldgs %
44.97%
Holding
105
New
25
Increased
29
Reduced
11
Closed
33

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$33.2M
2
BDX icon
Becton Dickinson
BDX
+$17.7M
3
ELV icon
Elevance Health
ELV
+$15.9M
4
TMO icon
Thermo Fisher Scientific
TMO
+$14.3M
5
DGX icon
Quest Diagnostics
DGX
+$13.7M

Top Sells

Rank Stock Value
1
WBA
Walgreens Boots Alliance
WBA
+$28.2M
2
ABBV icon
AbbVie
ABBV
+$24.6M
3
CRL icon
Charles River Laboratories
CRL
+$17.6M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$16.4M
5
ISRG icon
Intuitive Surgical
ISRG
+$15.9M

Sector Composition

Rank Sector Weight
1 Healthcare 95.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PODD icon
51
Insulet
PODD
$9.91B
$5.04M 0.48%
+25,000
New +$4.51M
QDEL icon
52
QuidelOrtho
QDEL
$940M
$4.98M 0.47%
+150,000
New +$6.14M
RLAY icon
53
Relay Therapeutics
RLAY
$4.42B
$4.89M 0.46%
750,000
+25,000
+3% +$171K
SGRY icon
54
Surgery Partners
SGRY
$1.99B
$4.76M 0.45%
+200,000
New +$5.13M
CRBP icon
55
Corbus Pharmaceuticals
CRBP
$185M
$4.53M 0.43%
+100,000
New +$4.21M
ISRG icon
56
Intuitive Surgical
ISRG
$141B
$4.45M 0.42%
10,000
-40,000
-80% -$15.9M
CPRX
57
DELISTED
Catalyst Pharmaceutical
CPRX
$4.26M 0.4%
+275,000
New +$4.28M
ROIV icon
58
Roivant Sciences
ROIV
$25.4B
$4.23M 0.4%
400,000
-200,000
-33% -$2.19M
KROS icon
59
Keros Therapeutics
KROS
$212M
$3.88M 0.37%
85,000
+45,000
+113% +$2.42M
HOLX
60
DELISTED
Hologic
HOLX
$3.71M 0.35%
+50,000
New +$3.75M
ETNB
61
DELISTED
89bio
ETNB
$3.6M 0.34%
450,000
+150,000
+50% +$1.34M
DYN icon
62
Dyne Therapeutics
DYN
$4.97B
$3.53M 0.34%
+100,000
New +$2.91M
SRRK icon
63
Scholar Rock
SRRK
$6.46B
$3.33M 0.32%
400,000
+75,000
+23% +$917K
CABA icon
64
Cabaletta Bio
CABA
$452M
$3.18M 0.3%
425,000
– –
EDIT icon
65
Editas Medicine
EDIT
$455M
$3.15M 0.3%
675,000
+225,000
+50% +$1.27M
APGE icon
66
Apogee Therapeutics
APGE
$10.2B
$3.15M 0.3%
80,000
+40,000
+100% +$1.94M
NRIX icon
67
Nurix Therapeutics
NRIX
$2.73B
$3.13M 0.3%
+150,000
New +$2.34M
FATE icon
68
Fate Therapeutics
FATE
$318M
$2.79M 0.26%
850,000
+650,000
+325% +$2.85M
NGNE icon
69
Neurogene
NGNE
$702M
$2.55M 0.24%
+70,000
New +$2.47M
SYRE icon
70
Spyre Therapeutics
SYRE
$9B
$2.35M 0.22%
100,000
– –
KURA icon
71
Kura Oncology
KURA
$882M
$2.06M 0.2%
+100,000
New +$2.06M
RVNC
72
DELISTED
Revance Therapeutics, Inc.
RVNC
$1.28M 0.12%
+500,000
New +$1.71M
A icon
73
Agilent Technologies
A
$42.2B
– –
-30,000
Closed -$4.37M
ABBV icon
74
AbbVie
ABBV
$440B
– –
-135,000
Closed -$24.6M
ALGN icon
75
Align Technology
ALGN
$12.3B
– –
-15,000
Closed -$4.92M
1 2
3
4 5

Similar funds

CL
CSS LLC Chicago, Illinois $2.09B AUM 58.96% 1-Year Est. Return
ACM
Analog Century Management New York $2.09B AUM 186.85% 1-Year Est. Return
ACG
Aventail Capital Group New York $2.09B AUM 43.81% 1-Year Est. Return
NSUP
NLB Skladi upravljanje premozenja Ljubljana $2.09B AUM
TP
Third Point New York $2.08B AUM 27.04% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.08B AUM
TA
TruWealth Advisors Metairie, Louisiana $2.08B AUM 21.15% 1-Year Est. Return
AG
Avala Global New York $2.08B AUM 87.66% 1-Year Est. Return

Integral Health Asset Management's Q2 2024 Portfolio in Review

As of Q2 2024, Integral Health Asset Management held 105 positions worth $1.05B, down 2.3% from $1.08B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Integral Health Asset Management withdrew a net $44M in Q2 2024, closing 33 positions and reducing 11 holdings. Its most notable exit was Walgreens Boots Alliance, an estimated $28.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier.

Against the trend, Integral Health Asset Management opened a new position in Becton Dickinson worth $17.5M.

  • Integral Health Asset Management's largest Q2 2024 buy was Becton Dickinson: 75,000 shares worth $17.5M.
  • Integral Health Asset Management added most to Cytokinetics in Q2 2024, an estimated $33.2M increase.
  • Integral Health Asset Management's biggest Q2 2024 reduction was Intuitive Surgical, cutting an estimated $15.9M.
  • Integral Health Asset Management fully exited Walgreens Boots Alliance in Q2 2024, selling an estimated $28.2M.
  • Integral Health Asset Management's ten largest holdings make up 45% of its $1.05B portfolio in Q2 2024.
  • Integral Health Asset Management opened 25 new positions and closed 33 in Q2 2024.
  • Integral Health Asset Management's portfolio value fell 2.3% quarter-over-quarter to $1.05B.

Based on Integral Health Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.